Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1790
Name malignant mesothelioma
Definition A cell type cancer that has_material_basis_in mesothelial tissue that develops from the thin layer of tissue that covers many of the internal organs.
Source DiseaseOntology.org
Alt Ids DOID:6965 DOID:4487 DOID:7434
Path disease disease of cellular proliferation cancer cell type cancer malignant mesothelioma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01592383 Phase II Erlotinib Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Terminated USA 0
NCT02071862 Phase I Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Completed USA 0
NCT02293005 Phase II Alisertib Alisertib in Malignant Mesothelioma Completed USA 0
NCT02341625 Phase Ib/II BMS-986148 BMS-986148 + Nivolumab A Study of BMS-986148 in Patients With Select Advanced Solid Tumors Terminated USA | ITA | GBR | CAN | BEL | AUS 1
NCT02349958 Phase II Mitomycin C Cisplatin Doxorubicin Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Unknown status USA 0
NCT02357147 Phase II Cisplatin + Pemetrexed Disodium Amatuximab Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS) Terminated USA | ITA | GBR | FRA | DEU | AUS 0
NCT02372227 Phase I Defactinib + VS-5584 A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma Terminated USA | GBR 0
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ESP 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 15
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN | AUS 0
NCT02760797 Phase I Emactuzumab + Selicrelumab A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed USA | FRA | BEL 0
NCT02856425 Phase I Nintedanib + Pembrolizumab Trial Of Pembrolizumab And Nintedanib (PEMBIB) Recruiting FRA 0
NCT02860286 Phase II Tazemetostat Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma Completed USA | GBR | FRA 0
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Completed USA 0
NCT02977156 Phase I Ipilimumab + JX-594 Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) Completed FRA 0
NCT03007030 Phase II Brentuximab vedotin Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery Recruiting USA 0
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed USA 0
NCT03319537 Phase Ib/II MLN4924 Cisplatin + MLN4924 + Pemetrexed Disodium Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma Completed USA 0
NCT03477162 Phase 0 Metformin Metformin Pharmacology in Human Cancers: A Proof of Principle Study Terminated USA 0
NCT03502746 Phase II Nivolumab + Ramucirumab Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma Active, not recruiting USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03531840 Phase II Olaparib Olaparib in People With Malignant Mesothelioma Completed USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03546426 Phase I Aldesleukin + Pembrolizumab Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX) Recruiting ITA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA 0
NCT03654833 Phase II Bemcentinib + Pembrolizumab Rucaparib Abemaciclib Atezolizumab + Bevacizumab Dostarlimab-gxly + Niraparib Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST) Active, not recruiting GBR 0
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03872206 Phase Ib/II HPN536 Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Completed USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT04173338 Phase I Cabozantinib + Pemetrexed Disodium Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma Terminated USA 0
NCT04328844 Phase I IOA-244 A Study to Assess a PI3Kdelta Inhibitor (IOA-244) in Patients With Metastatic Cancers Active, not recruiting ITA | GBR 0
NCT04462809 Phase II Talazoparib Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO) Not yet recruiting 0
NCT04515836 Phase II Olaparib Olaparib in Patients With HRD Malignant Mesothelioma Recruiting USA 0
NCT04606381 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) Active, not recruiting USA | GBR | CAN 1
NCT04857372 Phase I IAG933 A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 0
NCT05047536 Phase I KZR-261 KZR-261 in Subjects With Advanced Solid Malignancies Recruiting USA 0
NCT05070247 Phase I TAK-500 Pembrolizumab + TAK-500 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05071014 Phase I Pembrolizumab A Study of Pembrolizumab and Cryoablation in People With Mesothelioma Active, not recruiting USA 0
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Recruiting FRA 1
NCT05238883 Phase I HFB200301 HFB200301 + Tislelizumab A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05275478 Phase Ib/II TNG908 Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors Recruiting USA | FRA 0
NCT05278975 Phase Ib/II Thiostrepton Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma Recruiting GBR 0
NCT05298592 Phase I BMS-986406 + Nivolumab BMS-986406 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Recruiting USA | ESP | BEL 3
NCT05380713 Phase II Durvalumab + Tremelimumab Cyclophosphamide + Durvalumab + Tremelimumab --- SMARTEST Trial--- Recruiting CAN 0
NCT05415098 Phase I APG-5918 Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05455424 Phase II Niraparib Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO) Recruiting GBR 0
NCT05538572 Phase I PRT3645 A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT05544929 Phase I KFA115 + Tislelizumab KFA115 A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers Recruiting USA | CAN 4
NCT05571839 Phase I SGN-BB228 A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors Recruiting USA | GBR | CAN 1
NCT05579366 Phase Ib/II PRO1184 PRO1184 for Advanced Solid Tumors (PRO1184-001) Recruiting USA 1
NCT05703854 Phase Ib/II CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma Recruiting USA 0
NCT05800964 Phase I AMG 305 Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. Recruiting USA | FRA | ESP | DEU | AUS 1
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Recruiting USA | ESP | AUS 0
NCT05944237 Phase Ib/II Atezolizumab + HTL0039732 HTL0039732 HTL0039732 in Participants With Advanced Solid Tumours Recruiting GBR 0
NCT06034860 Phase I MT-8421 + Nivolumab MT-8421 Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types Recruiting USA 0
NCT06051695 Phase Ib/II A2B694 A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) Not yet recruiting USA 0